Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18452459)

  • 1. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
    Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J
    Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma.
    Desoize B; Amico S; Larbre H; Coninx P; Jardillier JC
    Clin Biochem; 1991 Oct; 24(5):443-6. PubMed ID: 1760884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of two serum isoenzyme phosphatases as bone metastasis markers].
    Desoize B; Pourny C; Amico S; Larbre H; Jardillier JC
    Bull Cancer; 1990; 77(12):1211-21. PubMed ID: 2081281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma acid and alkaline phosphatase in patients with breast cancer.
    Nguyen M; Bonneterre J; Hecquet B; Desoize B; Demaille A
    Anticancer Res; 1991; 11(2):831-3. PubMed ID: 2064338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase.
    Curatolo C; Ludovico GM; Correale M; Pagliarulo A; Abbate I; Cirrillo Marucco E; Barletta A
    Eur Urol; 1992; 21 Suppl 1():105-7. PubMed ID: 1385127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoenzymes of alkaline and acid phosphatases as bones metastasis marker in breast cancer patients.
    Desoize B; Veiler V; Pourny C; Comoe L; Jardillier JC
    Anticancer Res; 1989; 9(4):1105-9. PubMed ID: 2817792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
    Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
    J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of prostate specific antigen that predict skeletal spread in prostate cancer.
    Pantelides ML; Bowman SP; George NJ
    Br J Urol; 1992 Sep; 70(3):299-303. PubMed ID: 1384921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
    Fosså SD; Waehre H; Paus E
    Br J Cancer; 1992 Jul; 66(1):181-4. PubMed ID: 1379059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer.
    Gerber G; Chodak GW
    Urology; 1991 May; 37(5):418-22. PubMed ID: 2024388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating levels of tartrate-resistant acid phosphatase in macrophage-activated lung disease.
    Kehely A; Moss DW
    Ann Clin Biochem; 1992 Mar; 29 ( Pt 2)():172-5. PubMed ID: 1626921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of pelvic lymph node metastases by a prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4M0 prostatic cancer.
    Waehre H; Wanderaas EH; Paus E; Fosså SD
    Eur Urol; 1992; 22(1):33-8. PubMed ID: 1385143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer.
    Miller PD; Eardley I; Kirby RS
    Br J Urol; 1992 Sep; 70(3):295-8. PubMed ID: 1384920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
    Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
    Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum osteocalcin in monitoring bone metastases in advanced prostatic cancer.
    Marcellini M; De Carli P; Abbolito MR; Mainiero G; Cantiani R
    Eur Urol; 1992; 21 Suppl 1():102-4. PubMed ID: 1385126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen and prostatic acid phosphatase in the detection of early prostate cancer and in the prediction of regional lymph node metastases.
    Wirth MP; Frohmüller HG
    Eur Urol; 1992; 21(4):263-8. PubMed ID: 1281102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.
    Kida T; Higuchi Y
    Oncology; 1983; 40(5):346-50. PubMed ID: 6621997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
    Hetherington JW; Siddall JK; Cooper EH
    Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tartrate-resistant acid phosphatase in serum of cancer patients.
    Lam KW; Dannaher C; Letchford S; Eastlund T; Li CY; Yam LT
    Clin Chem; 1984 Mar; 30(3):457-9. PubMed ID: 6365356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.